Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Servier Agrees to Buy Symphogen to Swell its Cancer Pipeline
Details : Servier will gain full ownership of Symphogen’s proprietary pipeline of oncology and immuno-oncology programs and Symphogen’s antibody discovery and development platform.
Product Name : Undisclosed
Product Type : Large molecule
Upfront Cash : Undisclosed
April 03, 2020
Details : Cellectis grants to Servier an expanded exclusive worldwide license to develop and commercialize all next generation gene-edited allogeneic CAR T-cell products targeting CD19.
Product Name : Undisclosed
Product Type : Cell and Gene therapy
Upfront Cash : $27.6 million
March 04, 2020
Reset All
